Skip to content
The Policy VaultThe Policy Vault

Praluent (alirocumab) — Cigna

Heterozygous Familial Hypercholesterolemia

Initial criteria

  • Prescriber confirms diagnosis of heterozygous familial hypercholesterolemia
  • Patient age ≥ 8 years
  • Patient has phenotypic confirmation of heterozygous familial hypercholesterolemia (examples may include LDL receptor, apolipoprotein B, PCSK9, or LDL receptor adaptor protein 1 gene involvement)

Reauthorization criteria

  • According to the prescriber, the patient has experienced a response to therapy (e.g., decreasing LDL-C, total cholesterol, non-HDL-C, or apolipoprotein B levels)